How Ketamine Works in the Brain

Ketamine has been used as an anesthetic for decades, so its basic pharmacology is well understood. What researchers are still working out is why, at much lower doses, it can shift mood and pain perception for some people — and why those shifts can outlast the time the medicine is actually in the body.

This page separates the two clearly: what counts as established pharmacology, and what is a leading theory still being tested. You should expect that distinction from any clinic that talks about brain science, because the gap between the two is where hype usually lives.

Glutamate is the brain's most common excitatory neurotransmitter — the chemical signal neurons use to activate one another. Ketamine blocks a particular glutamate receptor called the NMDA receptor, which is why it is classified as an NMDA receptor antagonist. That much is settled science, documented across decades of research.

Blocking NMDA receptors changes how glutamate signals move through circuits involved in mood, pain, and perception. It also produces ketamine's well-known short-term effects — dissociation, altered sense of time and body — which is why sessions happen under monitoring rather than at home.

The leading hypothesis for ketamine's longer-lasting effects goes like this: briefly blocking NMDA receptors appears to set off a downstream cascade — a surge in glutamate signaling through other receptors (called AMPA receptors), followed by activation of growth-related pathways inside neurons, including signals such as BDNF and mTOR. In animal and early human studies, that cascade is associated with synaptic plasticity: the formation and strengthening of connections between brain cells.

It is important to hold this idea at arm's length. The plasticity theory is genuinely promising and widely studied, but it is still a theory. Researchers have not established exactly which steps in the cascade matter for mood, or proven that plasticity changes are the reason some people feel better. Where the science is unsettled, we say so.

Most standard antidepressants act primarily on serotonin, norepinephrine, or related systems, and typically take weeks of daily use to reach full effect. Ketamine works on the glutamate system instead — a different target entirely. That different mechanism is one reason researchers became interested in ketamine for people whose depression had not responded to standard medications, as explored in randomized trials published in 2006 and 2013.

A different mechanism does not mean a superior one. Standard antidepressants and psychotherapy remain first-line treatments, and ketamine therapy — which is not FDA-approved for depression and is prescribed off-label — is generally discussed only after those have been given a fair trial.

Open questions include how durable any benefit is, why some people respond and others do not, what repeated dosing does over the long term, and how ketamine's effects interact with psychotherapy given alongside it. Anyone who tells you the science has settled these questions is overstating it.

What this means practically is simpler than the neuroscience: because mechanisms and long-term effects are still being worked out, careful screening, conservative dosing, in-clinic monitoring, and honest follow-up are what responsible care looks like. That is the standard we hold ourselves to.